Xenon Pharmaceuticals Files 8-K/A Amendment
Ticker: XENE · Form: 8-K/A · Filed: Oct 17, 2025 · CIK: 1582313
| Field | Detail |
|---|---|
| Company | Xenon Pharmaceuticals Inc. (XENE) |
| Form Type | 8-K/A |
| Filed Date | Oct 17, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $540,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, amendment, officer-changes
TL;DR
Xenon Pharma filed an amendment to its 8-K on Oct 15th, updating exec/director info.
AI Summary
Xenon Pharmaceuticals Inc. filed an amendment (8-K/A) on October 17, 2025, to a previous filing concerning events on October 15, 2025. The amendment pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It also includes other events and financial statements/exhibits.
Why It Matters
This amendment provides updated information regarding significant corporate governance and executive changes at Xenon Pharmaceuticals, which could impact investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and primarily concerns corporate governance updates, not immediate financial distress or major operational shifts.
Key Players & Entities
- Xenon Pharmaceuticals Inc. (company) — Registrant
- October 15, 2025 (date) — Earliest event date
- October 17, 2025 (date) — Filing date
- 3650 Gilmore Way Burnaby, British Columbia, Canada V5G 4W8 (address) — Principal Executive Offices
FAQ
What specific corporate governance changes are detailed in this 8-K/A filing?
The filing indicates updates related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements.
What is the exact date of the earliest event reported in this amendment?
The earliest event reported is dated October 15, 2025.
When was this amendment (8-K/A) filed with the SEC?
This amendment was filed on October 17, 2025.
What is Xenon Pharmaceuticals Inc.'s principal executive office address?
The principal executive offices are located at 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8.
Besides director and officer changes, what other information is included in this filing?
The filing also includes information on 'Other Events' and 'Financial Statements and Exhibits'.
Filing Stats: 1,558 words · 6 min read · ~5 pages · Grade level 10.9 · Accepted 2025-10-17 16:37:26
Key Financial Figures
- $540,000 — Mr. Kelly's annual base salary will be $540,000, and he will be eligible for an annual
Filing Documents
- xene-20251015.htm (8-K/A) — 64KB
- xene-ex10_1.htm (EX-10.1) — 202KB
- xene-ex99_1.htm (EX-99.1) — 20KB
- img2657600_0.jpg (GRAPHIC) — 235KB
- img2657600_1.jpg (GRAPHIC) — 235KB
- img2657600_2.jpg (GRAPHIC) — 235KB
- img189401473_0.jpg (GRAPHIC) — 20KB
- 0001193125-25-242583.txt ( ) — 1370KB
- xene-20251015.xsd (EX-101.SCH) — 30KB
- xene-20251015_htm.xml (XML) — 5KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 16, 2025, Xenon Pharmaceuticals Inc. (the "Company") announced that Thomas (Tucker) Kelly has been appointed to serve as the Company's Chief Financial Officer, effective October 15, 2025. In connection with his appointment, Mr. Kelly will serve as the Company's principal financial officer and principal accounting officer. Mr. Kelly, age 54, previously served as Executive Vice President, Chief Financial Officer and Treasurer of Deciphera Pharmaceuticals, Inc. from January 2019 until its acquisition by Ono Pharmaceutical Co., Ltd. in June 2024, and as Deciphera's Chief Financial Officer and Treasurer since February 2015. Before joining Deciphera, Mr. Kelly served as Chief Financial Officer of various public and private life sciences companies including AdvanDx, Inc., deCODE genetics, Inc., and Critical Therapeutics, Inc. Prior to these roles, Mr. Kelly was a life sciences investment banker at Robertson Stephens and Canaccord Adams, and earlier in his career was an attorney in the corporate and securities group of Foley Hoag LLP. Mr. Kelly earned a J.D. with honors from the University of Chicago Law School and a B.S. in Foreign Service, cum laude, from the Georgetown University School of Foreign Service. There are no arrangements or understandings between Mr. Kelly and any other person pursuant to which he was appointed as Chief Financial Officer. There are no family relationships between Mr. Kelly and any director or officer of the Company, nor does Mr. Kelly have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. In connection with his appointment as Chief Financial Officer, Mr. Kelly and the Company entered into a letter agreement that sets forth the terms and conditions of his employment (the "Employment Agreement"
01
Item 8.01 Other Events. On October 16, 2025, the Company issued a press release announcing the matters described above, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Employment Agreement, dated October 4, 2025, by and between the Company and Thomas Kelly. 99.1 Press Release issued by Xenon Pharmaceuticals Inc. dated October 16, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENON PHARMACEUTICALS INC. Date: October 17, 2025 By: /s/ Ian Mortimer Ian Mortimer President and Chief Executive Officer